Table V.
Molecular subtypes and metastatic sites in patients with metastatic breast cancer from the Surveillance, Epidemiology and End Results dataset (n=15,322).
| Metastatic sites | HR+/HER2− (n=9,222) | HR+/HER2+ (n=2,710) | HR-/HER2+ (n=1,406) | HR-/HER2- (n=1,984) | P-value |
|---|---|---|---|---|---|
| Bone | <0.001 | ||||
| Metastasis | 7,563 (82.0) | 1,931 (71.3) | 762 (54.2) | 1,043 (52.6) | |
| No metastasis | 1,659 (18.0) | 779 (28.7) | 644 (45.8) | 941 (47.4) | |
| Lung | <0.001 | ||||
| Metastasis | 2,787 (30.2) | 901 (33.2) | 573 (40.8) | 946 (47.7) | |
| No metastasis | 6,435 (69.8) | 1,809 (66.8) | 833 (59.2) | 1,038 (52.3) | |
| Liver | <0.001 | ||||
| Metastasis | 1,965 (21.3) | 1,062 (39.2) | 726 (51.6) | 651 (32.8) | |
| No metastasis | 7,257 (78.7) | 1,648 (60.8) | 680 (48.4) | 1,333 (67.2) | |
| Brain | <0.001 | ||||
| Metastasis | 542 (5.9) | 226 (8.3) | 178 (12.7) | 255 (12.9) | |
| No metastasis | 8,680 (94.1) | 2,484 (91.7) | 1,228 (87.3) | 1,729 (87.1) | |
| DLN | <0.001 | ||||
| Metastasis | 363 (3.9) | 165 (6.1) | 97 (6.9) | 126 (6.4) | |
| No metastasis | 8,859 (96.1) | 2,545 (93.9) | 1,309 (93.1) | 1,858 (93.6) |
Values are expressed as n (%). HR, hormone receptor; HER2, human epidermal growth factor receptor 2; DLN, distant lymph node. P-value pertains to comparison among all groups.